0001553350-22-000582.txt : 20220701 0001553350-22-000582.hdr.sgml : 20220701 20220701115923 ACCESSION NUMBER: 0001553350-22-000582 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220630 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220701 DATE AS OF CHANGE: 20220701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nemaura Medical Inc. CENTRAL INDEX KEY: 0001602078 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 465027260 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38355 FILM NUMBER: 221060339 BUSINESS ADDRESS: STREET 1: 57 WEST 57TH STREET CITY: MANHATTAN STATE: NY ZIP: 10019 BUSINESS PHONE: 44-1509-222-912 MAIL ADDRESS: STREET 1: 57 WEST 57TH STREET CITY: MANHATTAN STATE: NY ZIP: 10019 8-K 1 nmra_8k-070122.htm FORM 8-K
0001602078 false 0001602078 2022-06-30 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): June 30, 2022

NEMAURA MEDICAL INC.

(Exact name of registrant as specified in charter)

Nevada

(State or other jurisdiction of incorporation)

001-38355

  

46-5027260

(Commission File Number)   (IRS Employer Identification No.)

 

57 West 57th Street

Manhattan, NY

10019

(Address of principal executive offices) (Zip Code)
     
Registrant’s telephone number, including area code:  

+1 (646) 416-8000

 

N/A

(Former name or former address, if changed since last report)

     

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock NMRD The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 
 

 

Item 2.02. Results of Operations and Financial Condition.

  

On June 30, 2022, Nemaura Medical, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended March 31, 2022. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in the website is not a part of this current report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

     

Exhibit No.    

  

Description

   
99.1   Press release issued by the registrant on June 30, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 
 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 

  NEMAURA MEDICAL INC.
   
Date: July 1, 2022 By: /s/ Dewan F. H. Chowdhury
    Dewan F. H. Chowdhury
Chief Executive Officer

 

 

 

  

 EX-99.1 2 nmra_ex99z1.htm INVESTOR PRESENTATION OF THE REGISTRANT.

EXHIBIT 99.1

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022.

Corporate Highlights for FY2022:

  • Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited (“MSWL”), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a leading professional publication and direct to consumer via national papers with daily circulation exceeding 1.2 million
  • Recognized $503,906 in revenue for the fiscal year ending March 31, 2022
  • Signed a global commercial contract with MySugarWatch DuoPack Limited. Under terms of the deal, the Nemaura’s CGMs and sensors will be provided as Duo-Packs with prescription-only medicines that are widely prescribed for people with Type 2 diabetes. The initial Duo-Pack presentation will be launched as the first of these medicines loses its patent protection in the UK in the calendar fourth quarter of 2022. Over 2 million prescriptions are written for these medicines in the top 3 EU countries (by GDP) alone, representing a significant opportunity
  • Launched beta trials of a metabolic health program using a body-worn glucose sensor along with an AI mobile application, intended for employers and insurers as well as direct to consumer, as a form of wellness and preventative medicine platform
  • Tiger Partners Trading LLC, an investment advisor to Julian Robertson’s Tiger Management family office, acquired a 3.1% equity stake in the Company in February 2022
  • Appointed Dr. Arash Ghadar as Chief Operating Officer. Dr. Ghadar has taken the lead in supporting the commercial supply of product to our current and future licensees and global distributors
  • Completed two FDA audits in relation to the Company’s previous PMA submission and is continuing the dialogue with the FDA in relation to the PMA submission

“On the heels of successfully commercializing sugarBEAT® in fiscal 2022 and recognizing our first revenue from our UK licensee MySugarWatch Limited, our primary goal in fiscal 2023 is to expand our revenue by supporting the launch effort of MySugarWatch Limited in the UK. We expect additional purchase orders to support the UK launch, as well as the anticipated Duo-Pack launch later in calendar 2022. MySugarWatch Limited has already begun mass advertising through education and awareness campaigns to healthcare professionals and direct to consumers through the national press,” commented Dr. Faz Chowdhury, CEO of Nemaura.

“Furthermore, we are exploring additional new channels in other territories with our technology platform. We have also started to engage with large scale manufacturers to enable us to meet the strong worldwide diabetic monitoring demand, and any appreciable scale we can build in our business should be meaningful to shareholder value. We look forward to updating investors with additional corporate highlights as they unfold,” concluded Dr. Chowdhury.

 
 

 

FY2022 Financial Summary:

  • The fiscal year ended March 31, 2022 marked a pivotal milestone for the Company, as it commenced deliveries of sugarBEAT® to MSWL pursuant to the initial order placed in April 2021
  • Research and development expenses were consistent with the prior year at approximately $1.5 million. The Company’s historically more significant research and development expenses relating to clinical trials and improvements made to the sugarBEAT® device began to flatten out over the 2022 fiscal year
  • General and administrative expenses were $6,173,049 and $3,032,138 for the fiscal years ended March 31, 2022 and 2021, respectively. These expenses consisted of fees for legal, professional, consultancy, audit services, investor relations, insurance, advertising, and general and operational wages. The year-over-year increase in expenses were driven predominantly by increased wages, as the Company has increased headcount to support the operational scale-up process across both its UK and U.S. teams

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT®and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

 
 

 

Cautionary Statement Regarding Forward-Looking Statements:

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the “FDA”) reserves the right to re-evaluate its decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

 

 

 EX-101.SCH 3 nmra-20220630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nmra-20220630_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nmra-20220630_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jun. 30, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 30, 2022
Entity File Number 001-38355
Entity Registrant Name NEMAURA MEDICAL INC.
Entity Central Index Key 0001602078
Entity Tax Identification Number 46-5027260
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 57 West 57th Street
Entity Address, City or Town Manhattan
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10019
City Area Code (646)
Local Phone Number 416-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol NMRD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 nmra_8k-070122_htm.xml IDEA: XBRL DOCUMENT 0001602078 2022-06-30 2022-06-30 iso4217:USD shares iso4217:USD shares 0001602078 false 8-K 2022-06-30 NEMAURA MEDICAL INC. NV 001-38355 46-5027260 57 West 57th Street Manhattan NY 10019 (646) 416-8000 false false false false Common Stock NMRD NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nemauramedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nmra_8k-070122.htm nmra-20220630.xsd nmra-20220630_lab.xml nmra-20220630_pre.xml nmra_ex99z1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nmra_8k-070122.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "nmra_8k-070122.htm" ] }, "labelLink": { "local": [ "nmra-20220630_lab.xml" ] }, "presentationLink": { "local": [ "nmra-20220630_pre.xml" ] }, "schema": { "local": [ "nmra-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NMRA", "nsuri": "http://nemauramedical.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "nmra_8k-070122.htm", "contextRef": "From2022-06-30to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nemauramedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "nmra_8k-070122.htm", "contextRef": "From2022-06-30to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nemauramedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001553350-22-000582-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001553350-22-000582-xbrl.zip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